Published in J Immunol on November 21, 2012
Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. MBio (2013) 1.04
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. MBio (2013) 0.94
Striking a balance: fungal commensalism versus pathogenesis. Curr Opin Microbiol (2013) 0.86
Host immunity to Cryptococcus neoformans. Future Microbiol (2015) 0.85
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib. Case Rep Infect Dis (2016) 0.82
Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection. J Immunol (2014) 0.81
Toward identification of the genetic risk profile for cryptococcal disease in HIV-infected patients. MBio (2013) 0.78
Roles of Autophagy and Autophagy-Related Proteins in Antifungal Immunity. Front Immunol (2016) 0.77
Commentary: Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development. Front Microbiol (2015) 0.75
Innate Immune Responses to Cryptococcus. J Fungi (Basel) (2017) 0.75
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity (2005) 4.31
The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol (2010) 4.26
B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med (2000) 3.89
Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity (2000) 3.49
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Peripheral development of B cells in mouse and man. Immunol Rev (2004) 2.74
CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity (2002) 2.67
Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med (1991) 2.64
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun (1987) 2.63
Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun (1987) 2.61
B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity (2004) 2.60
Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun (1987) 2.50
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol (1994) 2.20
B-1 B cell development. J Immunol (2006) 2.16
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med (1991) 2.11
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
A single VH gene is utilized predominantly in anti-BrMRBC hybridomas derived from purified Ly-1 B cells. Definition of the VH11 family. J Immunol (1989) 2.05
Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol (2003) 2.00
An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells. J Immunol (1997) 1.94
Cloning and expression of murine Ig genes from single B cells. J Immunol Methods (2009) 1.73
Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun (1990) 1.72
Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun (1990) 1.70
Pivotal advance: peritoneal cavity B-1 B cells have phagocytic and microbicidal capacities and present phagocytosed antigen to CD4+ T cells. J Leukoc Biol (2011) 1.67
The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes. J Immunol (2003) 1.67
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J Immunol (1999) 1.61
Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect Immun (1986) 1.61
Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A (2009) 1.61
Dual role for B-1a cells in immunity to influenza virus infection. J Exp Med (2008) 1.60
Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One (2009) 1.59
The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol (2005) 1.43
Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding. EMBO J (1992) 1.42
Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. J Immunol (2005) 1.40
Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol Microbiol (2007) 1.38
Experimental cryptococcosis in normal and B-cell-deficient mice. Infect Immun (1979) 1.37
Identification of an antigen-specific B cell population. J Immunol Methods (2003) 1.36
Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med (2006) 1.36
Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect Immun (1994) 1.34
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med (2010) 1.29
Frequent occurrence of identical heavy and light chain Ig rearrangements. Int Immunol (1997) 1.29
An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun (2007) 1.26
Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Int Immunol (1995) 1.25
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
Mouse B-1 cell-derived mononuclear phagocyte, a novel cellular component of acute non-specific inflammatory exudate. Int Immunol (2001) 1.23
Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect Immun (1995) 1.21
Restricted immunoglobulin variable region gene usage by normal Ly-1 (CD5+) B cells that recognize phosphatidyl choline. J Exp Med (1989) 1.20
Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Trends Microbiol (2001) 1.17
The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol (2010) 1.15
Distinct B-cell lineage commitment distinguishes adult bone marrow hematopoietic stem cells. Proc Natl Acad Sci U S A (2012) 1.15
B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol (2010) 1.14
B-1a, B-1b and B-2 B cells display unique VHDJH repertoires formed at different stages of ontogeny and under different selection pressures. EMBO J (1995) 1.13
B-cell fate decisions following influenza virus infection. Eur J Immunol (2010) 1.12
Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells. Infect Immun (2005) 1.11
A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol (2001) 1.10
A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine (2009) 1.09
Lipophilic dye staining of Cryptococcus neoformans extracellular vesicles and capsule. Eukaryot Cell (2009) 1.08
Generation of B cell memory to the bacterial polysaccharide alpha-1,3 dextran. J Immunol (2009) 1.08
Antigen-specific memory in B-1a and its relationship to natural immunity. Proc Natl Acad Sci U S A (2012) 1.07
Cryptococcus neoformans cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan. Fungal Genet Biol (2009) 1.07
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect Immun (2004) 1.06
Antigen-specific antibody responses in B-1a and their relationship to natural immunity. Proc Natl Acad Sci U S A (2012) 1.05
A B cell superantigen-induced persistent "Hole" in the B-1 repertoire. J Exp Med (2000) 1.05
Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis (1999) 1.03
IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis (2009) 1.01
Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect Immun (2002) 1.01
Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun (2004) 0.97
Systematic design and testing of nested (RT-)PCR primers for specific amplification of mouse rearranged/expressed immunoglobulin variable region genes from small number of B cells. J Immunol Methods (2008) 0.95
Molecular dissection of antibody responses against pneumococcal surface protein A: evidence for diverse DH-less heavy chain gene usage and avidity maturation. J Immunol (2009) 0.95
μ-chain-deficient mice possess B-1 cells and produce IgG and IgE, but not IgA, following systemic sensitization and inhalational challenge in a fungal asthma model. J Immunol (2012) 0.95
A role for B cells in resistance to Cryptococcus neoformans in mice. Infect Immun (1997) 0.93
Genetic resistance to murine cryptococcosis: increased susceptibility in the CBA/N XID mutant strain of mice. Infect Immun (1985) 0.93
Role of CD5+ B-1 cells in EAE pathogenesis. Autoimmunity (2008) 0.92
Nitric oxide-dependent killing of Cryptococcus neoformans by B-1-derived mononuclear phagocyte. J Leukoc Biol (2006) 0.90
IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms. Am J Pathol (2012) 0.89
The function of conserved amino acids in or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan. Mol Immunol (2003) 0.88
Intact bacteria inhibit the induction of humoral immune responses to bacterial-derived and heterologous soluble T cell-dependent antigens. J Immunol (2009) 0.86
B-1 cells modulate the kinetics of wound-healing process in mice. Immunobiology (2009) 0.85
Development of the antibody repertoire as revealed by single-cell PCR of FACS-sorted B-cell subsets. Ann N Y Acad Sci (1995) 0.85
Terminal deoxynucleotidyl transferase is required for an optimal response to the polysaccharide α-1,3 dextran. J Immunol (2009) 0.83
Microbicidal property of B1 cell derived mononuclear phagocyte. Immunobiology (2009) 0.83
The nature of an in vivo anti-capsular polysaccharide response is markedly influenced by the composition and/or architecture of the bacterial subcapsular domain. J Immunol (2011) 0.83
Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibody. Cell Microbiol (2006) 0.83
Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans. Infect Immun (2009) 0.82
The skewed heavy-chain repertoire in peritoneal B-1 cells is predetermined by the selection via pre-B cell receptor during B cell ontogeny in the fetal liver. Int Immunol (2008) 0.81
B-1 cells are pivotal for in vivo inflammatory giant cell formation. Int J Exp Pathol (2005) 0.81
Differential idiotype utilization for the in vivo type 14 capsular polysaccharide-specific Ig responses to intact Streptococcus pneumoniae versus a pneumococcal conjugate vaccine. J Immunol (2012) 0.80
Limiting CDR-H3 diversity abrogates the antibody response to the bacterial polysaccharide α 1→3 dextran. J Immunol (2011) 0.80
The damage-response framework of microbial pathogenesis. Nat Rev Microbiol (2003) 4.07
Passive antibody therapy for infectious diseases. Nat Rev Microbiol (2004) 2.64
Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol (2003) 2.00
A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol (2006) 1.42
Accidental virulence, cryptic pathogenesis, martians, lost hosts, and the pathogenicity of environmental microbes. Eukaryot Cell (2007) 1.38
Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice. Infect Immun (2007) 1.36
New concepts in antibody-mediated immunity. Infect Immun (2004) 1.19
CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice. J Immunol (2010) 1.17
Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res (2006) 1.15
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect Immun (2004) 1.06
Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. MBio (2013) 1.04
Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing. MBio (2011) 1.03
Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect Immun (2007) 1.00
Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide. Infect Immun (2003) 0.99
Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis (2003) 0.99
Induced humoral immunity and vaccination against major human fungal pathogens. Curr Opin Microbiol (2002) 0.98
Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis (2013) 0.98
The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol (2009) 0.98
A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol (2007) 0.97
Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun (2004) 0.97
Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. Infect Immun (2007) 0.96
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. MBio (2013) 0.94
Microbial virulence results from the interaction between host and microorganism. Trends Microbiol (2003) 0.92
Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol (2008) 0.91
Commentary: IDSA guidelines for improving the teaching of preclinical medical microbiology and infectious diseases. Acad Med (2010) 0.90
What is a pathogen? Ann Med (2002) 0.90
The weapon potential of a microbe. Trends Microbiol (2004) 0.90
IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms. Am J Pathol (2012) 0.89
Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation. Clin Vaccine Immunol (2006) 0.88
Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency? Clin Infect Dis (2011) 0.87
The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response. Vaccine (2011) 0.85
Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8. Clin Vaccine Immunol (2010) 0.83
The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. Vaccine (2010) 0.80
The potential of antibody-mediated immunity in the defence against biological weapons. Expert Opin Biol Ther (2005) 0.79
VH3 gene expression in children with HIV infection. J Infect (2004) 0.79
"Anti-virulence" genes--further muddling the lexicon? Response from Arturo Casadevall and Liise-anne Pirofski. Trends Microbiol (2003) 0.79
CD8+ T cells and risk for bacterial pneumonia and all-cause mortality among HIV-infected women. J Acquir Immune Defic Syndr (2012) 0.78
V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons. Clin Vaccine Immunol (2011) 0.75